We are pleased to invite you to the launch event of the PsyPal project, funded by the European Union, exploring the use of psilocybin in palliative care. The event will take place at the European Parliament in Brussels, kindly hosted by MEP Cyrus Engerer on 9th April from 12:15 to 13:45. It will be held under the auspices of the MEP Interest Group on Brain Health and Neurological Conditions and the MEP Action Group for the Medical Use of Psychedelics.

On behalf of the MEP Action Group for the Medical Use of Psychedelics, we warmly invite you to an event at the European Parliament, focusing on the potential of psychedelic therapies within the evolving EU pharma legislation context. This event marks the first meeting organized under the umbrella of the recently formed MEP Action Group. The key focus of the meeting will be on discussing the creation of a supportive regulatory environment to stimulate innovation in novel mental health treatments, particularly in the promising field of psychedelic therapies.

REGISTRATION REQUIRED

We are thrilled to announce the launch of the Members of the European Parliament Action Group for the Medical Use of Psychedelics (MEP AG), a platform to promote collective action for safe, responsible, and effective psychedelic treatments. The MEP AG, comprised of MEPs from seven EU nations, will be an important vehicle for change. PAREA, along with PsychedelicsEUROPE, provides secretariat support for the Group.

In the last few years, we have witnessed incredible progress in the area of psychedelic science. Now, we need to start moving the discussions about psychedelic-assisted therapies from the scientific conferences to much wider audiences, including policymakers.

On 6th December, we organized our first policy meeting in the European Parliament, looking at the basic ingredients of psychedelic novel treatments captured in the event’s title: “Psychedelic-assisted therapies in the treatment of brain disorders”.

Over 400 people registered for online and in-person attendance, including many EU and government officials. This is a clear sign that Europeans start looking for evidence-based education on psychedelic medicines.

To further shape the discussions on the responsible and safe roll-out of those treatments in the future, at the event, PAREA launched “An appeal to the European Union institutions and Member States”.

We bring together 15 members, including EU patient advocacy groups in the field of mental health, neurology and chronic pain, scientific associations – neuropsychopharmacologists and cancer societies, psychedelic foundations, as well as industry partners. We will be launching this partnership on 23rd June, 2pm – 4pm CEST.